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Abstract
Background: Absorbed dose estimates for pediatric patients require pharmacokinetics that are, to the extent
possible, age-specific. Such age-specific pharmacokinetic data are lacking for many of the diagnostic agents
typically used in pediatric imaging. We have developed a pharmacokinetic model of [18F]fluorodeoxyglucose (FDG)
applicable to premature infants and to 0- (newborns) to 5-year-old patients, which may be used to generate
model-derived time-integrated activity coefficients and absorbed dose calculations for these patients.
Methods: The FDG compartmental model developed by Hays and Segall for adults was fitted to published data
from infants and also to a retrospective data set collected at the Boston Children’s Hospital (BCH). The BCH data set
was also used to examine the relationship between uptake of FDG in different organs and patient weight or age.
Results: Substantial changes in the structure of the FDG model were required to fit the pediatric data. Fitted rate
constants and fractional blood volumes were reduced relative to the adult values.
Conclusions: The pharmacokinetic models developed differ substantially from adult pharmacokinetic (PK) models
which can have considerable impact on the dosimetric models for pediatric patients. This approach may be used as
a model for estimating dosimetry in children from other radiopharmaceuticals.
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Background
The radiation exposure resulting from medical imaging
has become a public safety concern [1–3]. Dose reduc-
tion for pediatric patients is particularly important since
such patients are considered to be at increased risk for
cancer owing to the enhanced radiosensitivity of their
tissues and the longer time period over which stochastic
radiation effects may manifest [4, 5].
Guidelines on the amount of activity to administer for
pediatric nuclear medicine imaging are based on expert
consensus of best practices [6, 7]. Methods based on
balancing activity administration with whole-body pho-
ton fluence or diagnostic image quality to arrive at an
optimal administered activity have also been examined
[8–11]. Optimization efforts would benefit by the avail-
ability of pharmacokinetic data for radiopharmaceuticals
commonly used in pediatric nuclear medicine imaging.
An extensive set of absorbed dose estimates and corre-
sponding pharmacokinetic data has been published by
the International Commission on Radiological Protec-
tion (ICRP) for many radiopharmaceuticals [12, 13]. The
tabulated calculations include absorbed and effective
doses to children. The biokinetic models used in these
calculations, however, are typically derived from adult
data, and the applicability of these models to children has
not been ascertained. There are a number of studies that
provide pharmacokinetic (PK) data for fluorodeoxyglucose
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(FDG) in pediatric patients [14–19]. Few to none of these
studies, however, include PK data for tissues other than
brain and, in one case, bladder [15]. In this work, we de-
rive an [18F]-FDG model for early-age pediatric patients
(newborns to 5-year-olds) based on an established [18F]-
FDG model applicable to adults [20], which is made ap-
plicable to pediatric patients by adjusting the model and
fitting it to a combination of published data and retro-
spective data collected at Boston Children’s Hospital
(BCH). The latter data set was also used to examine the
relationship between FDG uptake in different organs and
patient weight or age. Such relationships will be useful as
input into image simulation and diagnostic image quality
evaluation tasks as described previously [10].
Methods
Overall approach
To arrive at a pharmacokinetic FDG model applicable to
pediatric patients, we started with a published FDG PK
model applicable to adults [20]. Using data from the lit-
erature [21] and a data set from BCH, the model was ad-
justed and used to fit the combined measured and
literature-derived data set. In consultation with the insti-
tutional review board (IRB), the use of already collected,
anonymized, imaging data for the purposes of this study
was deemed exempt from IRB review.
Newborns to 5-year-olds FDG pharmacokinetic data
Thirty-five patients (19 males and 16 females; age range,
2 weeks to 5 years; mean age, 1 year 4 months; patient
weight ± SD, 11.47 ± 4.73 kg) who underwent whole-
body [18F]-FDG PET studies at Boston Children’s
Hospital between November 2009 and March 2015 were
used to extract organ PK. As quality control, annual
tests, and SUV cross calibration consistency tests of
PET/CT system have been performed by medical physi-
cists regularly, the quantification of the FDG measure-
ment in this study can be relied even over a time span of
6 years. Patients received 5.55 MBq/kg [18F]-FDG intra-
venously as a bolus. Except for one 2-week-old infant
who received 20 MBq, patients weighing less than or
equal to 4.7 kg received 26 MBq. The range of adminis-
tered activities was 20 to 126 MBq. The diagnostic
exams were primarily for cancer diagnosis and staging.
Characteristic details of the patients are presented in
Table 1. Patients fasted at least for 4–6 h before injec-
tion. Imaging was acquired at approximately 60–
126 min after injection using the Biograph mCT PET/
CT system (Siemens Medical Solutions). As the retro-
spective data were used, the variability in time was due
to a number of factors, including the difference of sus-
pected diagnosis and the practicalities associated with
imaging for each pediatric patient. The majority of pa-
tients (31 of 35 patients) were scanned from the skull to
the lower thigh. The whole-organ percent injected activ-
ity in various organs (brain, heart wall, lungs, kidneys,
and liver) was obtained from the [18F]-FDG PET images.
Region of interests (ROIs) were manually drawn to cover
the entire brain if the field of view covered the entire
brain (25 of 31 patients). Otherwise (heart wall, lungs,
kidneys, and liver), we used the interpolation method to
determine the organ masses in order to eradicate the un-
certainty from indistinct boundary of PET images espe-
cially in pediatrics to get better results of quantification.
When the field of view included only a portion of the
brain, ROIs on 3–4 consecutive transaxial planes
through the brain were used to measure the organ activ-
ity concentration (Bq/g assuming unit mass density). In
this latter group, the activity concentrations were multi-
plied by the brain masses interpolated from the age- and
weight-specific University of Florida pediatric phantom
series by matching the patients with the closest height
and weight phantom in the library [22]. This approach
was also used to obtain whole-organ activity for the
lungs, heart wall, kidneys, and liver. For organs other
than the brain, the ICRP values were very similar to the
University of Florida phantom series values, and the
former were used for scaling. The regions selected for
activity concentration did not include tumors, and we
make the assumption that scaling these regions by
whole-organ mass appropriately reflects normal tissue
uptake of FDG. In the case of the heart wall, ROIs were
delineated around the boundary of the heart wall in each
patient. If the heart wall contour could not be distinctly
differentiated from the heart region, the ROIs encom-
passed the whole heart instead. All measured data were
decay-corrected to the time of injection for each patient.
If this was not already done implicitly by the scanner,
then we performed an explicit decay correction. The
whole-organ activities were then divided by the adminis-
tered activity and multiplied by 100 to obtain percent
injected activity (%IA) as a function of time after
injection.
FDG compartmental model for premature infants
A compartmental modeling package, SAAM II (The
Epsilon Group, Charlottesville, VA), was used for model
fitting [23]. We used the whole-body adult FDG phar-
macokinetic compartment model developed by Hays and
Segall [20] and fitted it to partial data collected from in-
fants. The premature infant pharmacokinetic data were
derived from a report published by Niven and Nahmias
[21]. In brief, these authors collected two consecutive
45-min dynamic PET scans in very low birth weight in-
fants. The first scan was over the head, and the second
was over the chest region. The time-activity curves for
the brain, heart wall, lungs, and kidneys were then
generated.
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Model fitting to the premature infant data was ob-
tained by adjusting the adult model parameters of each
compartment that directly exchanges FDG with the
plasma. The exchange rate between the plasma and
erythrocyte compartments was also adjusted in this ini-
tial fitting phase. These initial fits were performed using
brain FDG exchange values obtained from Huang et al.
[24] which consisted of gray matter and white matter
with bidirectional exchange of FDG between plasma and
rapidly and slowly exchanging FDG compartments. We
eliminated the distinction between white and gray mat-
ter and only retained the distinction between rapidly and
Table 1 Patients’ characteristic data
Patient Sex Age (months) Weight (kg) Activity (MBq) Acquisition time after
injection (min)
Provisional/suspected diagnosis
(reason for PET/CT examination)
1 F 11 8.3 51.8 93 Rhabdomyosarcomaa
2 F 16 10.4 57.3 83 Neurofibromatosis 1 (abdominal/right flank pain)
3 F 3 4.5 27.1 94 Ewing’s sarcomab
4 F 4 7.3 38.4 79 Suspected pelvic carcinoma
5 F 10 5.9 31.0 69 Retroperitoneal sarcoma s/p chemotherapy
(assess for tumor activity)
6 F 3 4.0 25.9 60 Infantile adenocarcinomab
7 F 0.5 3.1 19.6 60 Infantile myofibromatosisa
8 F 16 11.6 64.0 84 Rhabdomyosarcomaa
9 M 6 10.0 58.8 126 Suspected left scalp Ewing’s sarcoma
10 M 9 7.7 44.4 97 Suspected pheochromocytomaa
11 M 8 9.6 50.0 125 Suspected malignant liver lesionb
12 F 36 12.4 80.3 74 Rhabdomyosarcoma s/p therapya
13 F 36 12.0 69.5 86 Rhabdomyosarcoma s/p therapyb
14 F 36 11.6 64.0 71 Rhabdomyosarcoma s/p therapyb
15 F 12 9.1 51.0 66 Infantile fibrosarcoma of pelvis s/p therapya
16 M 60 18.0 64.2 70 Diffuse large B cell lymphoma stage IVa
17 M 7 8.6 30.6 78 Hodgkin’s lymphoma s/p chemotherapya
18 F 48 16.0 91.2 81 Localized Ewing’s sarcomaa
19 M 48 15.1 82.9 73 Neurofibromatosis 1 (tumor activity evaluation)
20 F 13 7.3 40.7 60 Suspected malignant pelvic massb
21 M 24 12.4 81.2 85 High-risk neuroblastoma s/p therapya
22 M 9 10.5 94.8 113 Multifocal inflammatory myofibroblastic tumor of
the lungs s/p chemotherapya
23 F 10 9.9 58.8 109 B cell lymphomaa
24 F 7 8.1 48.1 117 Anaplastic large-cell lymphoma s/p therapya
25 F 11 7.0 37.4 88 Hepatoblastoma s/p chemotherapya
26 F 11 10.5 57.1 106 Suspected left renal cell carcinomaa
27 M 23 12.6 79.1 89 Suspected rhabdomyosarcoma
28 M 24 12.7 75.6 69 Right calf alveolar rhabdomyosarcomaa
29 M 36 13.8 81.4 117 Stage IV neuroblastoma s/p therapya
30 M 36 14.3 74.0 83 Stage IV neuroblastoma s/p therapya
31 M 48 21.7 121.4 82 Rhabdomyosarcomaa
32 M 60 22.0 125.8 119 Spinal neurofibromaa
33 F 60 20.1 116.6 81 Suspected neck LN in thyroid cancerb
34 M 60 16.6 92.9 83 Metastatic glomus tumora
35 M 60 16.8 96.9 75 Malignant rhabdoid tumor s/p therapya
aEvaluation for staging and/or response (post therapy)
bEvaluation for metastasis
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slowly exchanging brain compartments. The fraction of
blood volume was also gradually adjusted in order to ob-
tain the best fit of the brain compartment model.
In fitting the lungs and heart wall, we expanded the
model from a single compartment sink to two compart-
ments that exhibit bidirectional exchange of FDG with
the plasma. The fraction of blood volume in each com-
partment was also adjusted. The urine compartment in
the adult FDG model was modified to represent the kid-
neys, and a bidirectional exchange with the plasma was
added. The bidirectional rate constants between the
plasma and kidneys were also adjusted. The compart-
mental structure associated with the liver and other tis-
sues was retained as described in the adult FDG model.
FDG compartmental model for 0- to 5-year-olds
To create the pediatric (newborns to 5-year-olds) model,
the FDG model of Hays and Segall was initially fitted to
the pharmacokinetic data reported by Niven and
Nahmias, as described above, and then to the data ob-
tained from BCH. The compartmental structures were
kept in accordance with the infant model. As the acqui-
sition time spanned a range between 60 and 126 min
after injection for 35 patients, the data were binned into
5-min intervals and the mean and a standard deviation
for the data falling into each bin was calculated and used
as part of the model fitting process. Human FDG biodis-
tribution data at multiple time points are not available
for pediatric patients. As a result, the data obtained from
multiple patients spanning different acquisition times
were fitted into the model. We adjusted the transfer rate
constant parameters between the compartment gradually
for the brain, lungs, heart wall, kidneys, and liver to fit
the model to these data. The SAAM II software will then
generate time-integrated activity curve of the model fit-
ted to the observed data based on a nonlinear least-
squares regression algorithm. The blood volume fraction
in each compartment, representing the blood physically
contained in an organ or tissue relative to the total-body
blood volume, was also changed. The kinetic parameters
associated with rapidly and slowly exchanging tissue
compartments were retained as in the infant model;
however, the bidirectional exchange of the FDG between
the plasma and erythrocytes had to be adjusted. The dif-
ferential equations and parameter definitions describing
both models are provided in Additional file 1.
Fits to organ concentration vs weight
Imaging data obtained from BCH were nominally col-
lected at a single time point. As noted above, the actual
imaging times ranged from 60- to 126-min post-
injections. To examine the relationship between organ
activity concentration and patient weight, we binned the
imaging data to two time intervals, 60 to 81 min and
82–126 min with 15 and 20 data points in each bin, re-
spectively. For each time interval, the following function
was fitted using the MATLAB program to obtain the
organ activity concentration vs whole-body mass data
set:
%IA=g ¼ a•weightb þ c•weightd ð1Þ
where a, b, c, d are the fitted parameter values.
Binning the data in two different time-interval lengths
would be useful for observing the different results of
the percent injected activity of the FDG uptake in
each organ at the early time (60–81 min) and later
time (82–126) period for generating the image simu-
lation in the future study.
Results
Figure 1 depicts the compartmental model obtained by
the process described above. Figure 2 depicts the fits ob-
tained for the premature infants. Figure 3 shows the fits
obtained from the BCH data set. The error bar repre-
sents the standard deviation of %IA for each time point
obtained from multiple patients. The BCH data are at
the model-derived maximum FDG uptake in brain, ran-
ging from 25 to 40 %IA. When available, data points
from the literature (infants and newborns) at early time
are also included in these plots for comparison (Fig. 3a).
In the brain, data from Niven and Nahmias are at earlier
times and fall substantially below the model fit. Likewise,
the data from Ruotsalainen et al. also are well below the
model fit. In the lungs (Fig. 3b), the data from Niven
Fig. 1 FDG compartment model used to fit the kinetic data in
premature infants and newborns to 5-year-olds
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and Nahmias overlap in time with the BCH data and
have similar clearance kinetics but are more than two-
fold greater, ranging from 2 to 1.5 %IA while the BCH
data show lung uptake that is below 1 %IA. This is pos-
sibly because the patients in the Niven and Nahmias
study suffered from lung infections. In the heart wall
(Fig. 3c), the Niven and BCH data overlap with a percent
uptake ranging from more than 2 %IA to less than half
of a percent. The BCH data for the kidneys (Fig. 3d)
range from 2.5 %IA at the earlier time interval to
0.5 %IA at the later time interval. These data may be
grouped into two distinct sets, one that closely matches
the PK model and another set of points with similar kin-
etics, but with kidney %IA that is below the first group.
The latter data points (shown in red) are all obtained ex-
clusively from newborns and are also closer to the Niven
and Nahmias data points. In the liver (Fig. 3e), the
model provided a good fit to the BCH data with %IA
varying from slightly more than 4 to approximately 2.
No literature reports of liver PK in pediatric patients
could be found. As with the kidneys, data points made
up exclusively from newborns were below the model fit.
In Table 2, the parameter values used to fit the prema-
ture infant data of Niven and Nahmias (Fig. 2) and the
retrospective BCH imaging data (Fig. 3) are compared
with the original adult model parameters. The parameter
set that fit the BCH data differed substantially from the
adult values but was generally similar to the values ob-
tained by fitting the premature infant data set. Table 3
lists the time-integrated activity coefficient (TIAC)
Fig. 2 Plot of time-activity curves of the source organs that derived
from the premature infant model
Fig. 3 a–e Plot of BCH data and model-derived curves obtained from of each source organ. The error bars represent the standard deviation for
each time point derived from the variability of %IA in multiple patients in each bin of 5-min intervals. The SD was also considered for the
compartmental model fitting. In cases when literature data are available (e.g., brain, lungs, heart wall, and kidneys), these data points have been
plotted to compare with the model fit to the BCH data. In the lungs, heart wall, kidneys, and liver, data points that are exclusively derived from
patients <1 year old (newborns) are indicated in red. Other points (blue) are a composite of binned newborns and 1- to 5-year-olds
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obtained for each organ. These values correspond to the
area under the time-activity curve of each organ. TIAC
values obtained from the PK model are compared with
values reported by Niven and Nahmias. In Table 4, the
model-derived fractional blood volumes obtained from
the model fits are compared with ICRP 106 values and
with the original FDG model values. The biggest differ-
ences between ICRP 106 and the pediatric model values
are for the lungs and for the brain.
Figure 4 depicts the BCH data as %IA in each organ
against total body weight. The plots show the expected
segmentation of newborns (red) from 1- to 5-year-olds
(blue) by weight. A substantial variation in FDG uptake
is observed for all tissues. The greatest percent variation
is in the heart wall with max (4.66 %IA) to min
(0.23 %IA) ratio of approximately 20. The variation in
%IA in lungs is also high with a max-to-min ratio
(MMR) of 17. The variation in brain was lowest, with
MMR ≈ 2. Except for brain, there was no clear trend in
%IA with body weight or correspondingly a distinction
between newborns and 1- to 5-year-olds. In the brain, a
modest trend indicating reduced whole brain FDG up-
take at lower weight and age can be discerned. In other
tissues, there is a consistent pattern in which data from
four low-weight newborn patients (No. 3, 5, 6, and 7 on
Table 1) show a greater uptake than that seen for all of
the other patients. These four patients are in large part
responsible for the MMR values noted above and also
Table 2 Parameter values fitted to the premature infants and newborns to 5-year-olds FDG model
Parameter Premature 0- to 5-year-olds Adults
Plasma to erythrocytes (k1) 5.82E−02 5.31E−04 4.80E+00
Erythrocytes to plasma (k2) 1.16E−01 6.88E+01 8.07E+00
Plasma to fast brain (k3) 6.12E−02 3.70E−03 1.02E−01
Fast brain to plasma (k4) 1.30E−01 1.00E−01 1.30E−01
Fast brain to slow brain (k5) 6.62E−02 1.00E+00 6.20E−02
Slow brain to fast brain (k6) 9.57E−04 9.57E−04 6.80E−03
Plasma to lungs (k7) 7.20E−04 5.00E−06 1.70E−03
Lungs to plasma (k8) 6.46E−04 6.50E−04 –
Plasma to heart wall (k9) 1.72E−04 8.00E−07 5.30E−03
Heart wall to plasma (k10) 1.16E−07 5.50E−01 –
Plasma to kidneys (k11) 7.57E−04 2.75E−03 –
Kidneys to plasma (k12) 2.26E−02 5.50E−02 –
Plasma to fast liver (k13) 1.72E−02 2.00E−02 6.80E−02
Fast liver to plasma (k14) 2.19E−02 3.00E+00 2.19E−01
Fast liver to slow liver (k15) 1.20E−06 1.50E−03 1.80E−02
Plasma to fast “other” (k16) 1.32E+00 4.20E−02 3.71E−01
Fast “other” to plasma (k17) 2.76E+00 8.90E−02 1.02E−01
Fast “other” to slow “other” (k18) 3.62E−03 9.47E−03 1.67E−02
Blood volume fraction in brain 2.20E−02 1.35E−01 2.20E−01
Blood volume fraction in lungs 9.00E−02 3.00E−02 1.50E−01
Blood volume fraction in heart 2.50E−02 3.10E−02 6.90E−02
Blood volume fraction in liver – 9.80E−02 2.43E−01
Table 3 Time-integrated activity coefficient (TIAC) derived from the newborn FDG model compared with the published data
Organ TIAC (h)
Hays and Segall Niven and Nahmias Premature 0- to 5-year-olds
Brain 2.20E−01 ± 0.09 2.82E−01 ± 0.07 2.76E−01 1.15E−00
Lungs 7.00E−02 ± 0.03 4.80E−02 ± 0.03 7.00E−02 1.90E−02
Heart wall 1.30E−01 ± 0.06 1.80E−02 ± 0.01 2.70E−02 3.20E−02
Kidneys – 1.20E−02 ± 0.01 1.10E−02 4.60E−02
Liver 1.50E−01 ± 0.05 – – 1.09E−01
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for the absence of a consistent pattern in uptake vs body
weight shown in Fig. 4. With these data absent, every
organ shows lower FDG uptake at lower body weight.
Figures 5 and 6 depict the same data set but in terms
of tissue concentration rather than %IA. We examine
this relationship during the earlier (60–81 min) (Fig. 5)
and later (82–126 min) (Fig. 6) time period. The fit relies
on the first data point for the later bin of time points,
but the bin of earlier time points supports the observa-
tion at low weight. However, the data points were not
weighted in the fitting process. As we do not at this time
have a physiological basis for using the quadratic func-
tion, rather chose this as the best phenomenon logical fit
to the observations. The latter remains useful for studies
endeavoring to predict FDG concentration in different
tissues of pediatric patients. During both time periods, it
is clear that the concentration of FDG in each organ in-
creases with decreasing patient weight. This relationship
appears to be more robust for all organs at early time
because there was a greater span in the weights available
at early time (see Table 1). It is possible that this obser-
vation is a result of using a minimal administered activ-
ity for pediatric patients below a certain weight. This
would increase the blood concentration with decreasing
weight and is consistent with circulating blood as the
main source of FDG activity in normal tissue [25].
Table 5 lists the fitted parameter values for Eq. 1 used to
fit these data. The equation and parameter values can be
used to estimate the concentration in different organs at
the imaging time point for pediatric patients in the
weight range shown. Such data are useful for image
simulation studies wherein an estimate of the activity
Table 4 List of percent blood volume predicted by the FDG newborn model compared with values for the adult in ICRP 106 and
the original FDG adult model
Organ Fraction blood volume (%)
Adults (ICRP 106) Adults (Hays and Segall) Premature 0- to 5-year-olds
Brain 1.2 –a 2.2 13.5
Lungs 12.5 15 9 3
Heart wall 1.0 (same listed has coronary tissue) 6.9 (includes coronary artery) 2.5 3.1
Liver 10 24.3 – 9.8
aHays and Segall paper referred to Huang et al. brain model and did not explicitly list a fractional blood volume for brain
Fig. 4 a–e The relationship between the patient body weight and percent injected activity in each source organ for newborns (red) and 1- to
5-year-olds (blue). Each data point corresponds to an individual patient
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concentration in each organ as a function of patient
weight is needed to generate a simulated image at the
imaging time point.
Discussion
The goal for every pediatric molecular imaging study is
to obtain the best diagnostic information employing the
highest quality standards, in the shortest period of time,
and with the lowest patient radiation exposure [26]. The
Image Gently Campaign, an initiative of the Alliance for
Radiation Safety in Pediatric Imaging, has highlighted
the need to tailor diagnostic imaging procedures to chil-
dren so as to reduce their radiation exposure and poten-
tial cancer risk (http://www.imagegently.org, accessed
May 2015).
Almost all of the pharmacokinetic measurements
available for absorbed dose and risk calculations are
based on data collected from adults [13]. Using data
from the literature and from retrospective measurements
in different patients obtained from BCH, we have devel-
oped pharmacokinetic models for dosimetry and activity
concentration as a function of body weight to be used
for image simulation. Due to incomplete descriptions of
acquisition parameters and possible differences in
sensitivity, it is difficult to compare the data obtained
from the literature with the retrospective data we col-
lected at BCH [27]. Accordingly, we have superimposed
the data from the literature, when available, with BCH
data and model fits in Fig. 3 to highlight the serious
need for a consistent PK data set for pediatric patients.
Also, the BCH data are at a single nominal point in time
but, due to the practicalities associated with imaging
pediatric patients, there was a substantial variability in
imaging time. This allowed us to generate kinetic data
over the relative short time span defined by the BCH
data set. A more comprehensive data collection effort
would require an imaging protocol to image at add-
itional time points. Finally, as shown in Table 1, each
time point is derived from a single patient. Given the
limitations associated with pediatric imaging, it may be
difficult for a series of pediatric patients to be imaged
over multiple time points; rather, data from multiple pa-
tients spanning different acquisition times will need to
be assembled to establish a pharmacokinetic profile for
FDG and other agents used in pediatric imaging.
A number of interesting observations may be extracted
from the results presented above. We find that the %IA
in the brain obtained from BCH data is greater than
Fig. 5 Quadratic model used to estimate %IA/g of the FDG in each organ based on a function of patient weight for 60–81 min after injection.
Each data point corresponds to an individual patient
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predicted from the adult model and also from the pre-
mature infant data. Correspondingly, the brain TIAC de-
rived from the BCH data is approximately four times
greater than the other estimates shown in Table 3. The
TIAC in heart wall was about fivefold lower in the pre-
mature infants than the value for adults calculated using
the Hays and Segall FDG model. Brain and lung AUC
values for the fitted premature infant model were about
the same as those in the adult FDG model. The TIACs
obtained from fits to the BCH data (0- to 5-year-olds)
differ from the premature infant fits as might be ex-
pected given the nature of the premature infant data in
which these patients were being imaged due to lung in-
fections. Accordingly, the lung TIAC in this patient
population is 3.7-fold higher than that seen in the BCH
data. The brain, heart wall, and kidneys are 76, 16, and
76 % higher, respectively, in the BCH data set compared
to the Niven and Nahmias data set.
In Table 4, the model-derived estimates of the percent
blood volume for the brain, heart wall, lungs, and liver
are compared with published values. The fitted values
for both the premature infants and for the BCH data set
are greater for brain and heart wall relative to the values
for adults reported in ICRP 106. The fractional blood
volume for liver derived from the BCH data sets is the
same as that reported for adults. Liver data were not
reported by Niven and Nahmias. The fractional blood
volume in lungs of premature infants and newborns to
5-year-old children are 40 % and fourfold lower, respect-
ively, than the adult values reported in ICRP 106. The
model-derived premature infant heart wall percent tissue
blood volume is greater than in the ICRP 106 reference
adult by more than a factor of two. The Hays and Segall
Fig. 6 Quadratic model used to estimate %IA/g of the FDG in each organ based on a function of patient weight for 82–126 min after injection.
Each data point corresponds to an individual patient
Table 5 Fitting coefficients used to determine the %IA/g for
each organ at different time point for newborn FDG model
Organ Coefficient value
a b c d
Brain(60–81) 0.1118 −0.454 3.4798 −10.66
Brain(82–126) 0.0429 −0.1151 999.8 −5.4104
Lungs(60–81) −0.0163 −0.5690 0.0765 −0.9113
Lungs(82–126) 0.0023 −0.2488 2.4618 −2.9462
Heart wall(60–81) 0.7895 −1.5323 3.1637 −6.0397
Heart wall(82–126) 0.0514 −0.7949 56.945 −3.8659
Kidneys(60–81) 0.6594 −1.3418 567.51 −8.5901
Kidneys(82–126) 0.2427 −1.0152 47.191 −4.2647
Liver(60–81) −0.0011 0.2788 0.1163 −0.9573
Liver(82–126) 0.0586 −0.7806 62.2 −4.9917
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value for heart wall is about three times greater than the
value we obtained for the newborns. The newborn lung
percent blood volume is lower than the value listed in
ICRP 106 and in the adult FDG model. These compari-
sons, especially for the heart, are made difficult because
of the equivocal descriptions of blood content and
region described. For example, Niven and Nahmias
described a region of interest over the heart for imaging-
based measurements, which would presumably include
both parenchymal (heart wall blood) and heart contents.
The calculated TIAC, however, is ascribed to heart wall
based on the assumption that little activity would be in
the blood after 45 min, the time of imaging. The Hays
and Segall paper provides a footnote to the listed value
of percent blood volume indicating that the fractional
blood volume includes blood in the coronary artery
content.
Current pediatric absorbed dose estimates are per-
formed using adult pharmacokinetic data with S values
that account for the anatomical differences between
adults and children. The divergence, in both method-
ology, patient population and results obtained amongst
the different available sources of data for pediatric phar-
macokinetic modeling of FDG, highlights the need for
greater data collection of pediatric imaging agents.
Conclusions
Model-derived extrapolation of adult pharmacokinetic
data provides an initial approach to extending pediatric
PK data for use in dosimetry and image simulation.
Additional measurements over time are needed to fur-
ther validate these pediatric FDG models.
Additional file
Additional file 1: Pharmacokinetic model equations for premature
infants and newborn through 5-year-olds. Equations from SAAM II
compartment model used to derive TIAC in each source tissue (or
sample) for brain, lungs, heart wall, kidneys, and liver are also provided.
For each source organ or each sample, qi represents the differential
equations created internally and solved by SAAM II. (DOCX 290 kb)
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